

# Summer Training Institute for Randomized Clinical Trials Involving Behavioral Interventions

## Tab 6 Course Bibliography<sup>1</sup>

- \*Ader, R. & N. Cohen, Behaviorally conditioned immunosuppression and murine systemic lupus erythematosus, *Science*, 1982, 215, 1534-6.
- <sup>2</sup>**Armstrong, P. W., and C. D. Furberg, Clinical trial data and safety monitoring boards, *Circulation*, 1995, 91, 901-904.**
- Beecher, H. K., The powerful placebo. *JAMA*<sup>3</sup>, 1955, 27, 1602-1606.
- \*Begg, C., *et al.*, Improving the quality of reporting of randomized controlled trials, *JAMA*, August 28, 1996, 276 (3), 637-639.
- \*The Belmont Report: Ethical principles and guidelines for the protection of human subjects of research, April 18, 1979 (Department of Health, Education, and Welfare)
- Blumenthal JA, Jiang W, Babyak MA, Krantz DS *et al.* Stress management and exercise training in cardiac patients with myocardial ischemia. Effects on prognosis and evaluation of mechanisms. *Arch Intern Med*<sup>4</sup> 1997; 157:2213-2223.**
- \*Brody, B. A., *The Ethics of Biomedical Research: An International Perspective*. New York: Oxford University Press, 1998, pp. 72-75 & Chapter 7.
- \*Buyse M, *et al.* The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. *Statistics in Medicine*, 1999; 18, 3435-3451.
- \*Cappelleri, J. C., *et al.*, Large trials vs. meta-analysis of smaller trials: How do the results compare? *JAMA*, October 23/30 1996, 276 (16), 1332-1338.
- \*Code of Federal Regulations, Title 21, Section 314.126, Adequate and Well-controlled Studies.
- \*Code of Federal Regulations, Title 45, Part 46, Subpart A, Protection of Human Subjects.
- Coronary Drug Project Research Group, Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project, *N Engl J Med*<sup>5</sup>, 1980, 303: 1038-1041.
- DeMets, D. L., Data monitoring and sequential analysis: An academic perspective. *Journal of Acquired Immune Deficiency Syndrome*, 1990, 3 (Supplement), S124-S133.
- DerSimonian, R. Meta-analysis in the design and monitoring of clinical trials, *Statistics in Medicine*, 1996, 15, 1237-1248**

---

<sup>1</sup> An asterisk (\*) indicates a *Required Reading*. All required readings are located behind the tab in this binder for the associated lecture. When available, reprints of *Suggested Readings* are located immediately following this bibliography in alphabetical order of the author's last name.

<sup>2</sup> **Bold** type indicates a copy of the *Suggested Reading* article is reprinted.

<sup>3</sup> Journal of the American Medical Association

<sup>4</sup> Archives of Internal Medicine

<sup>5</sup> New England Journal of Medicine

## Bibliography

Diggle, PJ, Liang, KY, Zeger, SL, *Analysis of Longitudinal Data*. Oxford Science Publications, 1998. Chapter 1, pp. 1-22.

**Discussion, *Statistics in Medicine*, 1996, 15, pp. 1259-1262, 1281-1283, and 1307-1311.**

\*Domanski, M. J., and L. M. Friedman, Relative role of meta-analysis and randomized controlled trials in the assessment of medical therapies, *American Journal of Cardiology*, 1994, 74, 395-396.

**Frasure-Smith N, Lesperance F, Prince RH, Verrier P *et al*. Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. *Lancet* 1997; 350: 473-479.**

\*Frasure-Smith N & Prince R, Long-term follow-up of the Ischemic Heart Disease Life Stress Monitoring Program, *Psychosom Med*<sup>6</sup>, 1989, 51, 485-513.

\*Friedman LM, Furberg CD, and DeMets DL, *Fundamentals of Clinical Trials, Third Edition*. New York: Springer-Verlag, 1998, selected chapters.

\*Geller, N. L., and M. Proschan, Meta-analysis of clinical trials: A consumer's guide, *Journal of Biopharmaceutical Statistics*, 1996, 6 (4), 377-394.

Ghosh, D., Methods for analysis of multiple events in the presence of death, *Control Clin Trials*, 2000, 21, 115-126.

**Green, S. B., The advantages of community-randomized trials for evaluating lifestyle modification, *Controlled Clinical Trials*, 1997, 18, 506-513**

\*Hallstrom, A. P., & S. D. Sullivan, On estimating costs for economic evaluation in failure time studies, *Medical Care*, 1998, 36 (3), 433-436.

**Hallstrom, A. P., *et al*. Advantages and disadvantages of trial designs: A review of analysis methods for ICD studies, *Pace*, 2000, 23, 1029-1038.**

\*Harris, WS, *et al.*, A randomized controlled trial of the effects of remote, intercessory prayer on outcomes in patients admitted to the coronary care unit, *Arch Intern Med*, 1999, 159: 2273-2278.

\*Helsinki Declaration: Ethical Principles for Medical Research Involving Human Subjects (World Medical Association), revised October 2000.

\*Hrobjartson, A. & P. C. Gotzsche, Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. *New England Journal of Medicine*, 2001, 244, 1594-1602.

\*Infant Health and Development Program, Enhancing the outcomes of low-birth-weight, premature infants, *JAMA*, June 13, 1990, 263 (22), 3035-3042.

**Jones DA & West RR. Psychological rehabilitation after myocardial infarction: Multicentre randomised controlled trial. *BMJ*<sup>7</sup>, 1996; 313: 1517-1521.**

---

<sup>6</sup> Psychosomatic Medicine

<sup>7</sup> <http://www.bmj.com>

## Bibliography

Keefe, F. J., *et al.*, Pain coping skills training in the management of osteoarthritic knee pain: A comparative study. *Behavior Therapy*, 1990, 21, 49-62

\*Knatterud, G. L., *et al.*, Guidelines for quality assurance in multicenter trials: A position paper. *Controlled Clinical Trials*, 1998, 19, 477-493.

**Knatterud, G. L., Why clinical trials in the evaluation of life style evaluation? *Controlled Clinical Trials*, 1997, 18, 514-516.**

\*Letters to the Editor, *JAMA*, December 9, 1998, 280 (22), 1905-1908

\*Martin KA, *et al.*, Who will adhere? Key issues in the study and prediction of adherence in randomized controlled trials, *Controlled Trials*, 2000, 21, 195S-199S

\*Meinert C. L. *Clinical Trials: Design, Conduct and Analysis*. Chapter 16, "Quality Assurance." New York, New York: Oxford University Press, 1986, pages 166-176.

\*The Cardiac Arrhythmia Suppression Trial (CAST) Investigators, Preliminary report : Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction, *N Engl J Med*, 1989, 321: 406-412.

\*The MTA Cooperative Group, A 14-month randomized clinical trial of treatment strategies for Attention-Deficit/Hyperactivity Disorder, *Arch Gen Psychiatry*<sup>8</sup>, Dec 1999, 56, 1073-1086.

\*The MTA Cooperative Group, Moderators and mediators of treatment response for children with Attention-Deficit/Hyperactivity Disorder, *Arch Gen Psychiatry*, Dec 1999, 56, 1088-1096.

\*National Institutes of Health Policy and Guidelines for the Inclusion of Children as Participants in Research Involving Human Subjects, March 6, 1998.

\*National Institutes of Health Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research, March 18, 1994.

**Pocock S., *Clinical Trials*. New York: Wiley, 1984, Chapter 8.**

\*Powell LH, Unanswered questions in the Ischemic Heart Disease Life Stress Monitoring Program, *Psychosom Med*, 1989, 51, 479-484.

\*Rosa, Linda, *et al.*, A close look at therapeutic touch. *JAMA*, April 1, 1998, 279 (13), pp. 1005-1010, and Letters to the Editor, *JAMA*, December 9, 1998, 280 (22), 1905-1908

\*Shumaker, SA, *et al.*, Enhancing adherence in randomized controlled trials, *Controlled Trials*, 2000, 21, 226S-232S

\*Sieber WJ and Kaplan RM, Informed adherence: The need for shared medical decision making, *Controlled Trials*, 2000, 21, 233S-240S

Smith, Marcia Datlow, *et al.*, Facilitated communication: The effects of facilitator knowledge and level of assistance on output. *Journal of Autism and Developmental Disorders*, 1994, 24 (3), 357-367.

---

<sup>8</sup> Archives of General Psychiatry

## Bibliography

**Stampfer, M., Observational epidemiology is the preferred means of evaluating effects of behavioral and lifestyle modification, *Controlled Clinical Trials*, 1997, 18, 494-499.**

\*Sterling, T. D., *et al.*, Publication decisions revisited: The effect of the outcome of statistical tests on the decision to publish and vice versa, *The American Statistician*, 1995, 49 (1), 108-112.

**Task Force of the Working Group on Arrhythmias of the European Society of Cardiology, The early termination of clinical trials: Causes, consequences, and control. *Circulation*, 1994, 89 (6), 2892-2907.**

**Terrin, M. L., Individual subject random assignment is the preferred means for evaluating behavioral lifestyle modification, *Controlled Clinical Trials*, 1997, 18, 500-505.**

**Turner, C. F., *et al.*, Adolescent sexual behavior, drug use and violence: Increased reporting with computer survey technology, *Science*, 1998, 280, 867-873.**

\*Turner, J. A., *et al.*, The importance of placebo effects in pain treatment and research. *JAMA*, 1994, 271, 1609-1614.

\*Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical Literature, Call for comments on a proposal to improve reporting of clinical trials in the biomedical literature, *Annals of Internal Medicine*, 1994, 121 (11), 894-895.

**Yusuf, S., *et al.*, Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials, *JAMA*, 1991, 266 (1), 93-99.**